编者按：2024年欧洲肿瘤内科学会（ESMO）年会将于9月13~17日在西班牙巴塞罗那隆重举行。目前，ESMO官网已在线公布了入选壁报的题目。为方便读者了解消化肿瘤领域的最新进展，消化时讯小编特别整理了消化肿瘤领域中国专家的壁报汇总，供读者参考，如有缺漏和错误，欢迎留言指正。

结直肠癌

摘要号：557P

标题：Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individualsColonAiQ用于无症状个体结直肠癌筛查的真实世界评估的三年更新数据作者：Baohua Wang 北京

摘要号：537P

标题：Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE)立体定向消融放疗联合呋喹替尼和替雷利珠单抗治疗转移性结直肠癌：一项单臂前瞻性II 期试验（RIFLE）的最新结果作者：Yajie Chen 上海

摘要号：542P

标题：Long-term Outcomes of Neoadjuvant Toripalimab with or without Celecoxib in Patients with dMMR/MSI-H Locally Advanced Colorectal Cancer: 3-Month Treatment Cohort of The Randomized Phase 2 PICC Trial新辅助特瑞普利单抗联合或不联合塞来昔布治疗dMMR/MSI-H局部晚期结直肠癌患者的长期结果：随机Ⅱ期PICC试验的3个月治疗队列作者：胡华斌 广州 

摘要号：590P

标题：A deep-learning model to predict the completeness of cytoreductive surgery in colorectal cancer with peritoneal metastasis预测腹膜转移结直肠癌细胞减灭术完整性的深度学习模型作者：QingFeng Lin 广州

摘要号：546P  

标题：An artificial intelligence system integrating deep learning-proteomics, pathomics and clinicopathological features to determine risk of T1 colorectal cancer metastasis to lymph node一个整合深度学习蛋白质组学、病理组学和临床病理学特征的人工智能系统，用于确定T1期结直肠癌转移至淋巴结的风险作者：Yijiao Chen 上海

摘要号：560P  

标题：Circulating Tumor DNA Guided Therapeutic Strategies for Colorectal Cancer Patients with Multiple Small Pulmonary-limited Nodules – Updated results from the Open-Label, Prospective, Phase II Cohort Study循环肿瘤 DNA 指导结直肠癌伴肺局限性多发性小结节患者的治疗策略——开放标签、前瞻性、Ⅱ期队列研究的最新结果作者：Jinjia Chang 上海

摘要号：586P

标题：Clinical and Molecular Characteristics of Colorectal adenosquamous carcinoma: a multicenter retrospective study结直肠腺鳞癌的临床和分子特征：一项多中心回顾性研究作者：黄俊 广州

摘要号：539P

标题：Hepatic arterial infusion chemotherapy combined with Sintilimab and regorafenib as adjuvant therapy for colorectal liver metastasis patients with high risk of recurrent: a single-arm, Phase II study.肝动脉输注化疗联合信迪利单抗和瑞戈非尼作为复发高危结直肠肝转移患者的辅助治疗：一项单臂Ⅱ期研究作者：Lu Wang 王鲁

摘要号：589P

标题：Simultaneous Resection versus Staged Resection for Conversion Surgery for Initially Unresectable Colorectal Liver Metastasis: A Prospective Cohort Study初始不可切除结直肠癌肝转移的转化手术：同步切除 vs. 分期切除——一项前瞻性队列研究作者：许剑民 上海

摘要号：519P  

标题：Cetuximab plus capecitabine versus cetuximab as maintenance treatment in Chinese patients with RAS/BRAFwt metastatic colorectal cancer (mCRC): A phase III, multicenter, open-label, randomized study (C-CLASSIC study)西妥昔单抗联合卡培他滨 vs. 西妥昔单抗作为中国RAS/BRAFwt转移性结直肠癌（mCRC）患者的维持治疗：一项Ⅲ期、多中心、开放标签、随机研究（C-CLASSIC研究）作者：Dongsheng Zhang 广州

摘要号：563P

标题：Preliminary analysis in Protector-C study：a prospective, multicenter cohort of utilizing circulating tumor DNA (ctDNA) methylation as postoperative surveillance for colorectal cancer (CRC)Protector-C 研究中利用ctDNA甲基化作为结直肠癌术后监测的前瞻性多中心队列的初步分析作者：Zheng Liu 北京

摘要号：574P  

标题：First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 + bevacizumab (beva) in patients (pts) with advanced colorectal cancer (CRC): A phase I study首创药物PD-1/IL-2双特异性抗体融合蛋白IBI363+贝伐珠单抗 （beva）治疗晚期结直肠癌患者的Ⅰ期研究作者：林振宇 武汉

摘要号：1567P  

标题：Physicians' Adenoma Detection Rate and the Risk of Colorectal Cancer in Sequential Screening Programs：An Observational Cohort Study序贯筛查项目中医生腺瘤检出率和结直肠癌风险： 一项观察性队列研究作者：Li Xie 上海

摘要号：521P

标题：XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC: A Single-arm, Phase II Study.XELOX +Bev +替雷利珠单抗一线治疗MSS/pMMR RAS突变的mCRC：一项单臂Ⅱ期研究作者：Kai Ou 北京

摘要号：570P  

标题：A phase II clinical study of fruquintinib (Fru) combined with toripalimab (Tor) and short-course radiotherapy (SCRT) as neoadjuvant therapy for locally advanced rectal cancer (LARC)呋喹替尼联合特瑞普利单抗和短程放疗作为局部晚期直肠癌新辅助治疗的Ⅱ期临床研究作者：Ye Chen 成都

摘要号：576P

标题：Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: results from a phase 1 studyIBI354（抗HER2 ADC）在晚期胃肠道肿瘤患者中的安全性和有效性：Ⅰ期研究结果作者：龚继芳  北京

摘要号：564P

标题：Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in proficient mismatch repair or microsatellite stable (pMMR/MSS) low-lying early rectal cancer: preliminary findings from a prospective, multi-center, phase II trial (TORCH-E)短程放疗联合化疗和PD-1抑制剂治疗错配修复或微卫星稳定低位早期直肠癌：一项前瞻性、多中心、Ⅱ期试验（TORCH-E）的初步发现作者：Fan Xia 上海

摘要号：551P

标题：Efficacy prediction of chemoradiotherapy plus anti-PD-1/PD-L1 treatment by magnetic resonance imaging in MSS locally advanced rectal cancer磁共振成像对放化疗联合抗PD-1/PD-L1治疗MSS局部晚期直肠癌的疗效预测作者：汤文涛 上海

摘要号：556P

标题：Predicting the Efficacy of Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients Based on dynamic tumor-informed ctDNA-MRD基于动态肿瘤知情ctDNA-MRD预测直肠癌患者新辅助放化疗的疗效作者：Weiwei Xiao 广州

摘要号：566P  

标题：Impact of weekly irinotecan’s cycles during preoperative chemoradiotherpy in locally advanced rectal cancer: a post-hoc analysis of the CinClare study.局部晚期直肠癌术前放化疗期间每周伊立替康周期的影响：CinClare研究的事后分析作者：Ji Zhu 杭州

摘要号：602TiP

标题：Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 antibody for Non-metastatic Rectal Squamous Cell Carcinoma: A multicenter, prospective, single-arm, Phase II study.使用DDP/5-FU和PD-1抗体根治性同步放化疗治疗非转移性直肠鳞状细胞癌：一项多中心、前瞻性、单臂、Ⅱ期研究作者：黄俊 广州

摘要号：16P

标题：PTEN Deficiency Leads to Colorectal Cancer Immune Evasion via Atypical Keap1/Nrf2 Pathway.PTEN缺陷通过非典型的Keap1/Nrf2通路导致结直肠癌免疫逃避作者：RunKai Cai 广州

摘要号：15P

标题：TIGIT+ CD8+ T cells limit the efficacy of PD-L1 blockade plus chemoradiotherapy in MSS locally advanced rectal cancer via NECTIN2-TIGIT interplayTIGIT+ CD8+ T细胞通过NECTIN2-TIGIT相互作用限制PD-L1阻断联合放化疗对MSS局部晚期直肠癌的疗效作者：Zhehui Zhu 上海

摘要号：146P

标题：Biomarkers and intrinsic/acquired resistance mechanisms for Atezolizumab plus chemoradiotherapy in MSS locally advanced rectal cancer: An exploratory analysis of a single center, phase 2 study阿替利珠单抗联合放化疗治疗MSS局部晚期直肠癌的生物标志物和内在/获得性耐药机制：单中心Ⅱ期研究的探索性分析作者：汤文涛 上海

胰腺癌

摘要号：1526P

标题：Anti-PD-L1/TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine in previously untreated patients with locally advanced or metastatic pancreatic cancer: a multicenter, phase 1b/2 study抗PD-L1/TGF-βRII融合蛋白SHR-1701联合白蛋白结合型紫杉醇和吉西他滨治疗既往未治疗的局部晚期或转移性胰腺癌患者：一项多中心、Ⅰb/Ⅱ期研究作者：袁家佳 北京

摘要号：1530P

标题：preliminary result of a phase Ib study: efficacy and safety of FG-M108 plus gemcitabine and nab-paclitaxel in patients with Claudin18.2 positive locally advanced unresectable or metastaticpancreatic cancerIb 期研究的初步结果：FG-M108 联合吉西他滨和白蛋白结合型紫杉醇治疗 Claudin18.2 阳性局部晚期不可切除或转移性胰腺癌患者的疗效和安全性作者：Funan Liu 南京

摘要号：1533TiP

标题：A multicenter, open-label phase II study to evaluate the efficacy and safety of Pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without Toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) .评估Pimicotinib（CSF-1R 抑制剂）联合化疗联合或不联合特瑞普利单抗治疗晚期胰腺导管腺癌患者的疗效和安全性：一项多中心、开放标签的Ⅱ期研究作者：Xiaofei Zhang 上海

摘要号：1529P

标题：Fruquinitinib combined with nab-paclitaxel and gemcitabine (AG) as the first-line treatment for pancreatic ductal adenocarcinoma (PDAC) with liver metastases: An open-label, single-arm, single-center phase II clinical study呋喹替尼联合白蛋白结合型紫杉醇和吉西他滨作为胰腺导管腺癌（PDAC）伴肝转移的一线治疗：一项开放标签、单臂、单中心Ⅱ期临床研究作者：魏妙艳 上海

摘要号：14P  

标题：EED inhibition renders vulnerability to immunotherapy by rewiring ceramide metabolism in pancreatic cancerEED抑制通过重塑胰腺癌中的神经酰胺代谢增加对免疫治疗的敏感性作者：Fan Chen 广州

食管胃癌

摘要号：117P

标题：Methylome and transcriptome profiling of hepatoid adenocarcinoma of the stomach胃肝样腺癌的甲基化组和转录组分析作者：Shirong Zhang 杭州

摘要号：1432P

标题：Safety of laparoscopic D2 distal gastrectomy following neoadjuvant chemotherapy for locally advanced gastric cancer patients: A prospective multicenter trial (CLASS-03a)局部晚期胃癌患者新辅助化疗后腹腔镜D2远端胃切除术的安全性：一项前瞻性多中心试验 （CLASS-03a）作者：杨昆  成都

摘要号：1405P  

标题：Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for esophageal squamous cell carcinoma (EC-CRT-001 phase II trial)特瑞普利单抗联合根治性放化疗治疗食管鳞状细胞癌的长期生存和事后分析（EC-CRT-001 Ⅱ期试验）作者：Ruixi Wang 广州

摘要号：1407P  

标题：Pan-immune-inflammation value predicts the survival of patients with esophageal squamous cell carcinoma receiving immunotherapy and chemoradiotherapy: A pooled-analysis of two phase II trials泛免疫炎症值预测接受免疫治疗和放化疗的食管鳞状细胞癌患者的生存率：两项Ⅱ期试验的汇总分析作者：Xingyuan Cheng 广州

摘要号：1409P  

标题：Advancing esophageal cancer radiotherapy: AS-NeSt's 3D predictive proficiency for personalized dose distribution推进食管癌放疗：用于个性化剂量分配的AS-NeSt 3D预测能力作者：YUANHUA DUAN 上海

摘要号：1410P

标题：Efficacy of fruquintinib plus paclitaxel (F+PTX) in patients (pts) with prior immunotherapy (prior-IO): Subgroup analysis from FRUTIGA study呋喹替尼联合紫杉醇（F+PTX）对既往免疫治疗患者的疗效：FRUTIGA研究的亚组分析作者：沈琳 北京大学肿瘤医院

摘要号：1414P

标题：Iparomlimab and tuvonralimab (QL1706) with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: An open-label phase II studyIparomlimab和tuvonralimab（QL1706）联合根治性放化疗治疗局部晚期食管鳞状细胞癌：一项开放标签的Ⅱ期研究作者：Wencheng Zhang 天津

摘要号：1445P  

标题：Novel DNA methylation markers for early detection of cardia gastric adenocarcinoma and esophageal squamous cell carcinoma用于贲门胃腺癌和食管鳞状细胞癌早期检测的新型DNA甲基化标志物作者：Zhiyuan Fan 北京

摘要号：1461P

标题：Analysis of MET gene alterations in cfDNA samples from a phase II study of savolitinib in patients (pts) with MET-amplified gastroesophageal junction adenocarcinomas or gastric cancer (GEJ/GC)赛沃替尼Ⅱ期研究中，MET扩增的胃食管交界处腺癌或胃癌(GEJ/GC)患者cfDNA样本中MET基因的改变分析作者：彭智 北京

摘要号：1475TiP

标题：Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment for advanced G/GEJ cancer: A phase Ib/II clinical trial (FUNCTION)呋喹替尼联合信迪利单抗和CAPEOX一线治疗晚期G/GEJ癌：Ⅰb/Ⅱ期临床试验（FUNCTION）作者：Bei-Bei Chen郑州